Summit Therapeutics
- Market cap
- 14.32B
- P/E (TTM)i
- -16.17
- P/Bi
- 22.72
- EPSi
- -1.44
- Div yieldi
- 0.00%
- 52W posi
- 34%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Summit Therapeutics closed at 17.95, up 3.70%. The company carries a market value of roughly 14.32B, the #1207 most valuable US-listed company we track. Wall Street's 15-analyst consensus lands on Buy, with a price target averaging 29.58 (+65% from here). Over the past year the stock has ranged from 12.07 to 29.23; it now sits 34% up that band.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 4 weeks.
- Its last 8 Sell calls were actually followed by a +15% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -3.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 5.1% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 100.0% | Better than 100% |
| Operating margin | -9,018.2% | Better than 0% |
| Net margin | -11,174.8% | Better than 0% |
| Return on equity | -206.1% | Better than 1% |
| Return on invested capital | -200.7% | Better than 0% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 8.8% | Better than 74% |
| 6-month return | -10.1% | Better than 23% |
| 12-month return (ex latest month) | -20.5% | Better than 13% |
| Distance below 52-week high | 40.9% | Better than 13% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 9.9x | Better than 96% |
| Debt to assets | 2.8% | Better than 90% |
| Interest coverage | -24.5x | Better than 4% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 66.7% | Better than 40% |
| Upside to average target | 71.3% | Better than 91% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 17.31
- Open
- 17.10
- Day range
- 16.98 - 18.33
- Avg price
- 17.89
- Volume
- 8.18M
- Turnover
- 146.27M
- Turnover ratei
- 5.37%
- Volume ratioi
- 1.09
- Amplitudei
- 7.79%
- 52-week rangei
- 12.07 - 29.23
Valuation
- P/Ei
- -12.47
- P/E (TTM)i
- -16.17
- P/Bi
- 22.72
- EPSi
- -1.44
- Book value / shi
- 0.79
- Net profit
- -1.15B
- Net assets
- 630.22M
Share structure
- Market cap
- 14.32B
- Float capi
- 2.73B
- Shares out
- 797.75M
- Float sharesi
- 152.29M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-03-05
38.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-53.83M net over the window
Short interest
- Shares short
- 41.08M
- % of floati
- 5.15%
- Days to coveri
- 6.56
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Summit Therapeutics (SMMT)?
Summit Therapeutics last traded at 17.95. The quote on this page refreshes every few seconds while US markets are open.
What is Summit Therapeutics's market cap?
About 14.32B.
What is the P/E ratio of Summit Therapeutics?
The trailing twelve-month P/E is -16.17. The Valuation tab shows it against the stock's own five-year range.
Does Summit Therapeutics pay a dividend?
Summit Therapeutics does not currently pay a regular dividend.
Is Summit Therapeutics a buy according to analysts?
The consensus of 15 analysts is a Buy rating, with an average 12-month price target of 29.58, which implies 64.8% upside from the current price. This is not investment advice.
What is Summit Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Summit Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 06:49:11 · For reference only, not investment advice and not tailored to your situation.